alexa
Reach Us +44-1202-068036
Biofilm Dispersing NO-donor Cephalosporins Activated By β-Lactamase | 34848
ISSN: 2157-7609

Journal of Drug Metabolism & Toxicology
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Biofilm dispersing NO-donor Cephalosporins activated by β-Lactamase

World Congress and Exhibition on Antibiotics

Michael J Kelso, Nicolas Barraud, Scott A Rice, Staffan Kjelleberg, Saul N Faust, and Jeremy S Webb

University of Wollongong, Australia University of New South Wales, Australia Nanyang Technological University, Singapore University of Southampton, UK University of Southampton and University Hospital Southampton NHS Foundation Trust, UK

ScientificTracks Abstracts: J Drug Metab Toxicol

DOI: 10.4172/2157-7609.C1.002

Abstract
Low concentrations of nitric oxide (NO) have been shown to act as a signal that induces biofilm bacteria to disperse and revert to the free-swimming (planktonic) form. This finding unveiled an exciting new anti-biofilm paradigm; i.e. use of NO-donor compounds in combination with antibiotics to clear chronic biofilm infections, since it is well-known that planktonic bacteria are up to 1000x more susceptible to antibiotics and host immune defences than their better-protected biofilm counterparts. Based on this discovery, we have designed, synthesized and provided in vitro proof-of-concept validation for a novel class of cephalosporin-based NO-donor prodrugs (DEA-CPs) that can provide biofilm-targeted NO delivery. The targeted NO signal from DEA-CPs (activated by β-lactamases) induces biofilms to disperse and when used in combination with clinical antibiotics the compoundsare able to clear biofilms. The seminar will highlight key results in this area, including our latest efforts to translate DEA-CPs for use against chronic respiratory P. aeruginosa biofilms in cystic fibrosis patients.
Biography

Martin qualified in medicine from Newcastle University in 1982 and has worked as a GP since 1986. He obtained a Masters qualification in public health at Cambridge University in 1997. He has had a longstanding interest in applying evidence-based medicine to prescribing and therapeutics. He has previously worked for the National Prescribing Centre and the Department of Medicines Management at Keele University. From 1999, he has worked as a part-time GP in Conwy, North Wales, and initially worked as Medical Director for Conwy Local Health Board. Following the reorganisation of health services in Wales in 2009 he became Deputy then Acting Medical Director for the Health Board which manages all primary and secondary care NHS services in North Wales. He helped to organise and run the Diploma in Therapeutics at Cardiff University between 2005 and 2010. He chaired the New Medicines Group for Wales from inauguration in 2007 through to 2010. He is a Clinical Adviser on prescribing and evidence-based medicine for the Royal College of GPs, and is member of one of NICE’s technology appraisal committees.

Email: [email protected]

Relevant Topics
Leave Your Message 24x7
Top